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1. Introduction 
MicroRNAs (miRNAs) are a class naturally occurring small non-coding RNAs that control 
gene expression by targeting mRNAs for translational repression or cleavage (Krol et al., 
2010). Recent evidence has shown that miRNA mutations or mis-expression correlate with 
various human cancers, and that loss- or gain-of function of specific miRNAs contributes to 
breast epithelial cellular transformation and tumorigenesis (Esquela-Kerscher et al., 2006). 
miRNA expression profiling also revealed that miRNAs are differently expressed among 
molecular subtypes in breast cancer (Blenkiron et al., 2007; Iorio et al., 2005). 
There are large-scale molecular differences between estrogen receptor (ER) ┙-positive and 
ER┙-negative breast cancers (Perou et al., 2000; Sorlie et al., 2003). Endocrine therapy has 
become the most important treatment option for women with ER┙-positive breast cancer, 
and approximately 70% of primary breast cancers express ER┙. ER┙ is essential for 
estrogen-dependent growth, and its level of expression is a crucial determinant of response 
to endocrine therapy and prognosis in ER┙-positive breast cancer (Dowsett et al., 2008; 
Harvey et al., 1999; Yamashita et al., 2006). Multiple mechanisms involved in altering ER┙ 
gene expression in breast cancer have been proposed, including ER┙ gene amplification 
(Holst et al., 2007) as well as transcriptional silencing by DNA methylation of CpG islands 
within the ER┙ promoter (Giacinti et al., 2006) and mutations within the open reading frame 
of ER┙ (Herynk et al., 2004). However, expression levels of ER┙ in breast cancer tissues 
differ widely among patients (Yamashita et al., 2011), and frequently change during disease 
progression and in response to systemic therapies (Yamashita et al., 2009). It was reported 
that the microRNA miR-206 decreases endogenous ER┙ mRNA and protein levels in human 
MCF-7 breast cancer cells via two specific target sites within the 3’-untranslated region 
(UTR) of the human ER┙ transcript (Adams et al., 2007). We found that the expression levels 
of miR-206 were gradually decreased as ER┙ protein expression increased in breast cancer 
tissues, suggesting that miR-206 is a key factor for the regulation of ER┙ expression in 
human breast cancer (Kondo et al., 2008). Moreover, recent studies have shown that ER┙-
regulating miRNAs, miR-18a, miR-18b, miR-22, miR-193b, miR-302c, and miR-221/222, as 
well as miR-206, directly targeted ER┙ in 3’UTR reporter assays, and suggested that several 
miRNAs regulate ER┙ expression. 
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2. Estrogen receptor (ER) α expression in human breast cancer 
2.1 Expression of ERα in human breast cancer tissues 
2.1.1 ERα expression in normal and malignant breast epithelial cells 
ER┙ expression in normal and premalignant breast epithelial cells has been assessed by 
immunohistochemistry. It was reported that on average, normal premenopausal terminal 
duct lobular units contain about 30% ER┙-positive cells (Allred et al., 2004). In contrast, 
nearly all cells express very high levels of ER┙ in the majority of premalignant breast 
lesions, including atypical ductal hyperplasia, atypical lobular hyperplasia and lobular 
carcinoma in situ. DCIS (Ductal carcinoma in situ) shows various levels of ER┙ expression 
ranging from high levels of lower-grade lesions to low levels of higher-grade lesions, 
including entirely ER┙-negative. Furthermore, the wide range of ER┙ expression is observed 
in invasive ductal carcinoma. There is a substantial (~25%) subset of invasive breast cancers 
that does not contain any ER┙-expressing cells. The majority (~75%) of invasive breast 
cancers, however, does contain ER┙-expressing cells, but the proportion varies ranging from 
very low, to intermediate, to very high. We examined ER┙ expression in breast cancer 
tissues by immunohistochemistry using Allred score (Allred et al., 1998), and demonstrated 
that breast tumors show a wide range of ER┙ expression levels (Yamashita et al., 2011). 
Moreover, intensity of ER┙ expression is not equal among breast cancer cells in an 
individual tumor. Eastern cooperative oncology group compared the distribution of ER┙ 
protein expression by immunohistochemistry and ER┙ mRNA expression by quantitative 
reverse transcription (RT)-PCR in ECOG 2197 study (Badve et al., 2008). They reported that 
ER┙ mRNA expression in breast cancer tissues also showed continuous and the wide range. 
2.1.2 Role of expression levels of ERα in human breast cancer 
It is well established that expression levels of ER┙ govern response to endocrine therapy 
and prognosis in ER┙-positive human breast cancer. Allred and colleagues first reported 
that expression levels of ER┙ assessed by immunohistochemistry affected prognosis 
(Harvey et al., 1999). ER┙ status using Allred score was a highly significant predictor of 
disease-free survival for patients who received adjuvant endocrine therapy. Recently, 
relationship between expression levels of ER┙ and prognosis was analyzed in adjuvant 
endocrine therapy trials for postmenopausal breast cancer, and demonstrated that disease-
free survival or time to recurrence were significantly different according to expression levels 
of ER┙ (Dowsett et al., 2008; Viale et al., 2007). It was reported that the use of a cutoff of 1% 
staining cells for ER┙ indicated a better prognosis and at least some degree of endocrine 
responsiveness (Hammond et al., 2010). In the neoadjuvant endocrine therapy trial for 
postmenopausal women, correlation between expression levels of ER┙ assessed by Allred 
score and response to neoadjuvant endocrine therapy was analyzed (Ellis et al., 2001). It 
showed that letrozole response rates were superior to tamoxifen response rates in every ER┙ 
Allred score from 3 to 8, indicating that letrozole is more effective than tamoxifen regardless 
of the level of ER┙ expression. We also studied expression levels of ER┙ on pretreatment 
biopsies and post-treatment surgical specimens in postmenopausal patients with ER┙-
positive primary breast cancer who were treated with aromatase inhibitors for 6 months 
(Yamashita et al., 2009). We showed that ER┙ expression was decreased in post-treatment 
tumors compared to pretreatment specimens. On the other hand, we analyzed expression 
levels of ER┙ in primary breast cancer specimens from 75 metastatic breast cancer patients 
who received endocrine therapy on relapse, and analyzed the correlation between 
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expression levels of ER┙ and response to endocrine therapy and post-relapse survival 
(Yamashita et al., 2006). Our results indicated that patients with higher ER┙ expression 
responded significantly to endocrine therapy, and that patients with higher ER┙ expression 
had better survival after relapse. Moreover, we recently reported that patients whose breast 
tumors contained high ER┙ expression effectively responded to aromatase inhibitors and 
displayed longer time to progression during first-line endocrine therapy with aromatase 
inhibitors and time to endocrine therapy failure (Endo et al., 2011). 
2.2 Regulation of expression levels of ERα 
Multiple mechanisms involved in the regulation of ER┙ expression in breast cancer have 
been identified, including mutations of ER┙ gene (Herynk et al., 2004) and transcriptional 
silencing by DNA methylation within the ER┙ promoter (Gaudet et al., 2009; Giacinti et al., 
2006; Iwase et al., 1999). It was recently reported ER┙ gene amplification in breast cancer 
(Holst et al., 2007; Tomita et al., 2009). Holst and colleagues demonstrated that ER┙ gene 
amplification was frequent and more than 20% of breast cancers harbored genomic 
amplification by FISH analysis. They reported that ESR1 amplification was tightly linked to 
ER┙ protein expression, and that ESR1 amplification was also found in benign and 
precancerous breast diseases, such as atypical ductal hyperplasia, ductal carcinoma in situ 
and lobular carcinoma in situ. However, breast cancer patients show a wide range of ER┙ 
expression levels (Yamashita et al., 2011), and the levels of expression in individual patients 
change during disease progression and in response to systemic therapies (Yamashita et al., 
2009). Therefore, other mechanisms may also regulate ER┙ expression in breast cancer. 
2.2.1 miRNA biogenesis and function 
MicroRNAs (miRNAs) comprise a large family of ~21-nucleotide-long RNAs that have 
emerged as key post-transcriptional regulators of gene expression (Krol et al., 2010). In 
mammals, miRNAs are predicted to control the activity of ~50% of all protein-coding genes. 
Functional studies indicate that miRNAs participate in the regulation of almost every 
cellular process investigated so far and that changes in their expression are associated with 
many human pathologies. Primary miRNA transcripts are cleaved into 70- to 80-nucleotide 
precursor miRNA (pre-miRNA) hairpins by RNase III Drosha in the cell nucleus and 
transported to the cytoplasm, where pre-miRNAs are processed by RNA Dicer into 19- to 
25-nucleotide miRNA duplexes. One strand of each duplex is degraded, and the other 
strands become mature miRNAs, which, incorporated into the RNA-induced silencing 
complex, recognize sites in the 3’-UTR of the target mRNAs and cause translational 
repression or mRNA cleavage. miRNAs are a new player among gene regulation 
mechanisms, and their functions have not been fully explored but are known to include the 
regulation of cellular differentiation, proliferation and apoptosis. Recent evidence has 
shown that miRNA mutations or mis-expression are associated with various human cancers 
(Esquela-Kerscher et al., 2006). 
2.2.2 Regulation of expression levels of ERα by miRNAs 
Adams and colleagues first identified two potential miRNA miR-206 target sites within the 
3'-UTR of ER┙ mRNA via in Silico analysis (Adams et al., 2007). The validation assay 
revealed that both miR-206 target sites specifically interacted with miR-206, which in turn 
repressed the corresponding ER┙ mRNA and protein expression. They also demonstrated 
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that expression levels of endogenous miR-206 were significantly higher in ER┙-negative 
MDA-MB-231 cells than in ER┙-positive MCF-7 cells. Moreover, they showed that miR-206 
repressed ER┙ mRNA and protein expression in MCF-7 and T47D cells. We showed that 
miR-206 expression assayed by quantitative RT-PCR analysis was inversely correlated with 
ER┙ but not ER┚ mRNA expression in human breast cancer tissues (Kondo et al., 2008). 
Moreover, miR-206 expression levels were gradually decreased as ER┙ protein expression 
increased in human breast cancer. Transfection experiments revealed that introduction of 
miR-206 in estrogen dependent MCF-7 cells inhibited cell growth. Transfection of miR-206 
into MCF-7 cells suppressed ER┙ expression and inhibited cell growth in a dose-dependent 
manner. Furthermore, introduction of miR-206 produced a dose-dependent decrease of 
mRNA expression of ER┙-target genes, such as progesterone receptor, cyclin D1 and pS2. 
Adams and colleagues recently reported that miR-206 coordinately targeted mRNAs 
encoding the coactivator proteins SRC-1 and SRC-3, and the transcription factor GATA-3, all 
of which contribute to estrogenic signaling and a luminal A phenotype (Adams et al., 2009). 
Furthermore, they identified that miR-206 contributed to the epidermal growth factor (EGF) 
induced repression of ER┙ signaling in MCF-7 cells. 
2.2.3 MiRNAs that directly target ERα in human breast cancer 
Zhao and colleagues demonstrated that miR-221 and miR-222 were highly expressed in 
ER┙-negative breast cancer cells, and that miRNA in situ hybridization analyses also 
showed overexpression of miR-221 and miR-222 in ER┙-negative breast tumors (Zhao et al., 
2008). Recently, two groups reported several miRNAs that down-regulated ER┙ in breast 
cancer cells. They identified the target sites of miRNAs, such as miR-18a and b, miR-302, 
miR-193b, miR-22, and miR221/222 as well as miR-206, in the ER┙ 3’-UTR, and showed that 
these miRNAs inhibited estrogen signaling by directly targeting ER┙ mRNA (Leivonen et 
al., 2009; Pandey et al., 2009) (Fig.1). 
 
 
Fig. 1. Schematic representation of the human ER┙ mRNA and the predicted miRNA target 
sites. 
We recently analyzed expression levels of miRNAs that directly target ER┙, including 
miR-18a, miR-18b, miR-22, miR-193b, miR-221/222 and miR-302c in human breast cancer 
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samples by quantitative RT-PCR analysis (Yoshimoto et al., 2011). Our results showed 
that miR-18a expression was much higher in ER┙-negative than ER┙-positive tumors, 
with the expression levels of miR-18a not differing in ER┙-positive breast cancer as a 
function of ER┙ protein level. Surprisingly, expression levels of miR-193b and miR-221 
were significantly lower in ER┙-negative than ER┙-positive tumors, and the levels of 
these miRNAs gradually increased as ER┙ protein expression increased. There was no 
statistically significant association between miR-22 and ER┙ expression, and miR-302c 
expression was minimal in human breast cancer samples. Prognostic analysis showed that 
low miR-18b expression was significantly associated with improved survival in HER2-
negative breast cancer. Our results suggest that miRNAs that directly target ER┙ have 
distinct roles in not only regulating ER┙ but also regulating other target genes in human 
breast cancer, and that some miRNAs might be associated with characteristics of ER┙-
positive breast cancer. 
2.3 Role of miRNAs in breast cancer 
miRNAs can function as tumor suppressors and oncogenes (Esquela-Kerscher et al., 2006). 
The reduction or deletion of a miRNA that functions as a tumor suppressor leads to tumor 
formation. On the other hand, the amplification or overexpression of a miRNA that 
function as an oncogene results in tumor formation. Lu and colleagues first analyzed 
miRNA expression profiling in normal and tumor samples, and revealed global changes 
in miRNA expression (Lu et al., 2005). It was found that miRNA expression seems 
globally higher in normal tissues compared with tumors. Moreover, miRNAs are 
differentially expressed in various cancers. miRNA expression profiling also revealed that 
miRNAs are differently expressed among molecular subtypes in breast cancer (Blenkiron 
et al., 2007; Iorio et al., 2005). Iorio and colleagues first reported the miRNA gene 
expression profile in human breast cancer (Iorio et al., 2005). Compared with normal 
breast tissue, miRNAs are aberrantly expressed in human breast cancer. They also 
reported differentially expressed miRNAs associated with ER┙ expression, including 
miR-206. Blenkiron and colleagues analyzed miRNA expression in human breast cancer, 
and found that many miRNAs were differently expressed between breast cancer subtypes, 
such as luminal A, luminal B, HER2-positive, basal-like and normal-like (Blenkiron et al., 
2007). They also found significant association between miRNA expression profiling and 
clinicopathological factors such as ER┙ status and tumor grade. Furthermore, recent 
studies have demonstrated that loss- or gain-of function of specific miRNAs contributes to 
breast epithelial cellular transformation and tumorigenesis. The interconnections between 
miRNAs and tumor suppressor genes and oncogenes in breast cancer were summarized 
by Zoon and colleagues (Zoon et al., 2009). 
3. Conclusion 
It is well recognized that individual miRNA sequences can suppress the production of 
hundreds of proteins (Krol et al., 2010). Reduction of protein levels in this way is often 
modest, however, and many such RNAs probably collectively fine-tune gene expression. 
Accumulating evidence supports the hypothesis that the ability of miRNAs to 
simultaneously regulate many target genes makes them attractive candidates for regulating 
normal and cancer cells. miRNAs are potential therapeutic targets for more tailored 
treatment strategies for breast cancer. 
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